IL4I1: Function in Immune Suppression and Cancer

IL4I1, short for interleukin-4-induced gene 1, is an enzyme that breaks down aromatic amino acids and, in doing so, generates a cocktail of metabolites that collectively dampen immune responses. In the context of cancer, this makes it a powerful enabler of tumor immune evasion. The enzyme has drawn intense research interest in recent years partly because it may explain a high-profile failure in cancer drug development and partly because it operates through mechanisms that overlap with, but are distinct from, better-known immune checkpoints.

What IL4I1 Actually Does

IL4I1 belongs to a family of enzymes called L-amino acid oxidases. Its core job is to chew up aromatic amino acids, with phenylalanine as its preferred target, though it also processes tryptophan and tyrosine.¹ This selectivity for aromatic substrates is a relatively recent evolutionary specialization. Ancestral versions of the enzyme had a much broader appetite, acting on hydrophobic, polar, and positively charged amino acids alike, but the human form has narrowed its focus to aromatics.²

When IL4I1 breaks down phenylalanine, the reaction produces phenylpyruvate, hydrogen peroxide, and ammonia. When it processes tryptophan, the products include indole-3-pyruvate (I3P) and downstream metabolites like kynurenic acid and indole-3-aldehyde.³ Each of these products has its own downstream effects on immune cells and tumor biology, which is what makes IL4I1 so multifaceted as an immune suppressor.

Where the Enzyme Shows Up

IL4I1 is produced mainly by immune cells of myeloid origin, including macrophages and dendritic cells. B cells also express it. The signals that switch on IL4I1 production differ between these cell types in an interesting way: in macrophages and related cells, various pro-inflammatory signals trigger its expression through the transcription factors NF-κB and STAT1. B cells respond to some of the same triggers, but they also turn on IL4I1 in response to interleukin-4 signaling through a different pathway, and they do not respond to interferon-gamma the way myeloid cells do.⁴

This means IL4I1 can be switched on by inflammation itself, creating a feedback loop: the immune system mounts a response, and that very response triggers production of an enzyme that tamps the response back down. In healthy tissue, this kind of negative feedback prevents runaway inflammation. In tumors, it gets co-opted to protect cancer cells from immune attack.

How IL4I1 Suppresses T Cell Responses

The immune-suppressive effects of IL4I1 hit T cells from multiple angles simultaneously. The hydrogen peroxide generated by the enzyme is directly toxic to effector and memory T cells, the cells responsible for recognizing and killing threats. At the same time, the consumption of phenylalanine starves T cells of a building block they need to proliferate.³ On top of that, IL4I1 interferes with early signaling events that occur right after a T cell’s receptor recognizes its target. When IL4I1 is present during T cell activation, the signals downstream of the T cell receptor are weakened, and this suppressive effect is even stronger when the co-stimulatory signal from CD28 is involved.⁵

While effector T cells are being inhibited and starved, the conditions created by IL4I1 actually favor the development of regulatory T cells. These are the immune system’s peacemakers, cells that actively suppress other immune responses. Phenylalanine depletion and hydrogen peroxide production together shift the balance away from aggressive immune activity and toward tolerance.³ In a healthy body, this balance is essential. Inside a tumor, it is disastrous for the patient.

Reshaping the Tumor Microenvironment

IL4I1 does not just suppress T cells directly; it reshapes the entire neighborhood around a tumor to be more hospitable for cancer growth. One key mechanism involves macrophages, the immune cells that can either attack tumors or support them depending on their programming. Macrophages exist on a spectrum, with pro-inflammatory types at one end and anti-inflammatory, tissue-repair-oriented types at the other. IL4I1 pushes macrophages toward the anti-inflammatory end of this spectrum, boosting production of markers associated with tissue repair and suppressing inflammatory signaling.⁶ This is exactly the wrong direction when you want immune cells to fight a tumor.

In a melanoma mouse model, inactivating IL4I1 limited the recruitment of immunosuppressive myeloid cells and increased infiltration by the types of T cells that kill tumors, delaying both tumor development and the spread of metastases.⁷ Pan-cancer analyses across many tumor types have shown that IL4I1 is overexpressed in the majority of cancers studied, and its levels correlate with disease stage and overall survival outcomes.⁸⁹

The AHR Pathway and Protection from Ferroptosis

Perhaps the most consequential discovery about IL4I1 in recent years is its connection to a sensor protein called the aryl hydrocarbon receptor, or AHR. When IL4I1 breaks down tryptophan, the downstream products include indole-3-pyruvate, kynurenic acid, and indole-3-aldehyde. These metabolites activate AHR, which then switches on a broad program of gene expression that further suppresses immune activity and promotes tumor tolerance.¹⁰ Researchers confirmed that it is specifically the indole metabolites, not the products from phenylalanine breakdown, that drive this activation.

AHR activation does something else that matters for cancer: it helps tumor cells resist a form of cell death called ferroptosis, which is an iron-dependent process driven by the buildup of toxic lipid molecules in cell membranes. Indole-3-pyruvate acts as a direct free-radical scavenger and also triggers a broader antioxidant gene program that shields cells from ferroptotic death.¹¹ This anti-ferroptotic activity is a critical distinction between IL4I1 and the snake-venom enzymes it shares an evolutionary ancestor with. Venom L-amino acid oxidases kill cells by flooding them with hydrogen peroxide, but mammalian IL4I1 does not produce enough peroxide to be cytotoxic in the same way. Instead, its metabolite profile protects cells, which in a tumor context means protecting cancer cells from a death pathway the immune system might otherwise exploit.¹¹ The combined package of effects, immune suppression plus ferroptosis resistance plus AHR-driven tolerance, has led researchers to describe IL4I1 as a metabolic immune checkpoint.¹²

Why IDO1 Inhibitor Trials Failed and What IL4I1 Has to Do with It

This section requires some backstory. For years, a different enzyme called IDO1 was the star of tryptophan-metabolism-based cancer research. IDO1 breaks down tryptophan through a different chemical reaction, producing kynurenine, and it was a leading target for cancer immunotherapy. A major Phase III clinical trial tested an IDO1 inhibitor called epacadostat in combination with a PD-1 checkpoint inhibitor for melanoma. The trial failed spectacularly, showing no benefit over the checkpoint inhibitor alone. The result effectively collapsed an entire drug class overnight.

Subsequent analysis suggested that AHR, the receptor that drives immune suppression downstream of tryptophan metabolism, might have alternative activation pathways that IDO1 inhibitors simply could not block. IL4I1 emerged as a prime suspect. Studies have found that IL4I1 actually shows the strongest correlation with AHR activity across multiple human cancers, even stronger than IDO1 itself.¹³ Within tumor microenvironments, IL4I1 and IDO1 have overlapping expression patterns, especially in myeloid cells, and both enzymes generate metabolites that activate AHR and suppress ferroptosis.¹⁴ This overlap means that blocking IDO1 alone still leaves IL4I1 free to maintain AHR activation and immune suppression through its own metabolite output.

The implication is straightforward: if both enzymes feed into the same downstream suppressive pathway, you likely need to inhibit both to see a clinical benefit. Analysis of compensatory mechanisms following IDO1 inhibition has confirmed that alternative tryptophan-metabolizing enzymes, including IL4I1, can pick up the slack when IDO1 is blocked.¹⁵ This has given the field renewed energy around dual-inhibition strategies rather than targeting one enzyme at a time.

IL4I1 and Resistance to Checkpoint Immunotherapy

The connection between IL4I1 and immunotherapy resistance goes beyond the IDO1 story. In mouse melanoma models, tumors engineered to overexpress IL4I1 showed resistance to anti-PD-L1 therapy, one of the most widely used classes of checkpoint immunotherapy. The mechanism involved suppression of CD8-positive T cell infiltration into the tumor, essentially preventing the killer T cells from reaching the cancer cells even when the PD-L1 brake was released.¹⁶

A similar dynamic has been observed in blood cancers. In relapsed or refractory diffuse large B-cell lymphoma, IL4I1 expression enhanced immunosuppression through the same IDO-AHR-kynurenine signaling axis discussed above, reducing the effectiveness of PD-1 inhibitors combined with CAR-T cell therapy. When researchers knocked out IL4I1, the combination treatment worked better.¹⁷ In lung adenocarcinoma, IL4I1-expressing tumor-associated macrophages and tryptophan-metabolizing fibroblasts together created an environment of tryptophan degradation and AHR ligand accumulation that drove CD8-positive T cell exhaustion and resistance to anti-PD-1 treatment.¹⁸ The pattern is consistent across tumor types: IL4I1 creates a metabolic environment that undermines immunotherapy from within the tumor.

Early Efforts to Develop IL4I1 Inhibitors

Given all of this, developing drugs that block IL4I1 has become a priority for several research groups. The work is still in early preclinical stages, but one compound that has emerged from screening efforts is ZY-MY-111, a small-molecule inhibitor that blocks IL4I1’s ability to break down tryptophan. In laboratory tests, it showed reasonable potency and worked by competitively occupying the enzyme’s catalytic pocket. Mechanistically, it disrupted the tryptophan-to-AHR signaling chain in cells, and in animal models it reactivated CD8-positive T cell immune responses and suppressed tumor growth.¹⁹

Whether compounds like this will succeed where IDO1 inhibitors alone failed remains an open question. The logic of the dual-inhibition hypothesis is compelling on paper, but the history of cancer immunotherapy is littered with ideas that made perfect sense in mice and fell apart in human trials. The redundancy of tryptophan metabolism pathways, with IDO1, IDO2, TDO2, and IL4I1 all potentially compensating for each other, makes this a genuinely difficult pharmacological problem. Still, the identification of IL4I1 as a key driver of AHR-mediated immune suppression has opened a door that did not exist five years ago.

Roles Beyond Cancer

IL4I1’s immune-suppressive and anti-inflammatory properties are not inherently harmful. In fact, in the right context, they can be therapeutic. One striking example comes from research on demyelinating diseases. When IL4I1 was injected intravenously into mice with a model of multiple sclerosis at the onset of disease, it significantly reversed disease severity, with animals recovering from hindlimb paralysis. Post-mortem analysis showed reduced damage to nerve fibers in the spinal cord and decreased CD4-positive T cell populations.²⁰ Follow-up work showed that the metabolites produced by IL4I1’s enzymatic activity, the same aromatic acid byproducts that cause problems in tumors, reduced inflammatory activity in brain immune cells and created conditions favorable for the repair cells that rebuild the protective myelin sheath around nerves.²¹

Beyond the nervous system, IL4I1 also has antibacterial properties. Research has shown that the enzyme inhibits the growth of both gram-negative and gram-positive bacteria, likely through the hydrogen peroxide it generates during amino acid oxidation. This antimicrobial function adds another layer to IL4I1’s biological identity: it is not simply an immune suppressor but a multifunctional molecule whose effects depend heavily on context. In infection, it may help kill pathogens. In autoimmune disease, it may calm destructive inflammation. In cancer, those same calming properties become a liability.

An Ancient Enzyme with a Specialized Modern Role

IL4I1’s evolutionary history helps explain some of its unusual biology. The enzyme belongs to a family that is widespread across the animal kingdom, with relatives found in bony fish, amphibians, and reptiles. Mammalian IL4I1 clusters most closely with L-amino acid oxidases from fish, and the two share distinctive sequence features including specific amino acid changes near the active site and a unique two-codon deletion not found in other family members.²² This is a very old gene that has been continuously shaped by the demands of immune defense for hundreds of millions of years. The shift from broad substrate specificity to a preference for aromatic amino acids appears to have happened along the lineage leading to mammals, and it fundamentally changed the metabolite profile the enzyme produces, pushing it from a general antimicrobial weapon toward the specialized immunomodulatory role it plays today.² The ancestors of this enzyme in venomous animals kill cells outright through massive hydrogen peroxide production. Mammalian IL4I1 has dialed down that toxicity and traded it for a subtler, regulatory function, one that tumors have learned to exploit.